CheckMate 649: Nivolumab combinations in oesophageal and gastric cancers

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 19 / Springer Healthcare

CheckMate 649: Nivolumab combinations in oesophageal and gastric cancers

Oncology Gastrointestinal Cancer ESMO-2021

Description

Eric Van Cutsem comments on the CheckMate 649 study showing the continued benefit of adding nivolumab to chemotherapy as first-line treatment for oesophageal and gastric cancers but disappointing findings when combined with ipilimumab versus chemotherapy.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.